Related trials
PHS II vitamin C, 2008 - vitamin C vs placebo
POPADAD (antioxydant), 2008 - combination vs placebo
ARISE, 2008 - succinobucol vs placebo
PHS II vitamin E, 2008 - vitamin E vs placebo
WACS beta-caroten, 2007 - beta carotene vs placebo
WACS vitamin E, 2007 - vitamin E vs placebo
WACS vitamin C, 2007 - vitamin C vs placebo
WHS vitamin E, 2005 - vitamin E vs placebo
SUVIMAX, 2005 - combination vs placebo
PHS II beta carotene, 2003 - combination vs placebo
Tepel, 2003 - acetylcysteine vs placebo
WAVE (Waters), 2002 - combination vs placebo
HPS antioxidant, 2002 - combination vs placebo
HATS, 2001 - combination vs placebo
PPP, 2001 - vitamin E vs control
AREDS, 2001 - vitamin E vs placebo
HOPE, 2000 - vitamin E vs placebo
ASAP, 2000 - vitamin E vs placebo
WHS beta carotene, 1999 - beta carotene vs placebo
GISSI, 1999 - vitamin E vs control
NSCP (Green) beta carotene, 1999 - beta carotene vs placebo
MVP, 1997 - combination vs placebo
PHS beta carotene, 1996 - beta carotene vs placebo
CARET beta carotene, 1996 - beta carotene vs placebo
CHAOS, 1996 - vitamin E vs placebo
See also:
All cardiovascular prevention clinical trials
All clinical trials of antioxydants
All clinical trials of succinobucol
|
|
Treatments
Studied treatment |
succinobucol 300 mg once daily
|
Control treatment |
placebo
|
Patients
Patients |
patients with recent (14-365 days) acute coronary syndromes already managed with conventional treatments |
Inclusion criteria |
men and women (not of childbearing potential);18 years or older and have diabetes; or 60 years or older, or be 55 years or older and at least one of the following risk factors: low HDL cholesterol (
|
Exclusion criteria |
recent coronary revascularisation (percutaneous coronary intervention
|
Method and design
Randomized effectives |
3078 / 3066 (studied vs. control) |
Design |
Parallel groups |
Blinding |
double blind |
Follow-up duration |
24 mo (range 12-36 mo) |
Number of centre |
261 |
Geographic area |
Canada, US, UK, South Africa |
Hypothesis |
Superiority |
Primary endpoint |
CV death, MI, Stroke, UA, revasc |
Results
Endpoint
Studied treat. n/N
Control treat. n/N
Graph
RR [95% CI]
cardiovascular events
530 / 3078
529 / 3066
1,00 [0,89;1,11]
new-onset atrial fibrillation
107 / 2818
55 / 2787
classic
1,92 [1,40;2,65]
cardiovascular death, MI, stroke
207 / 3078
252 / 3066
0,82 [0,69;0,98]
new-onset diabetes
30 / 1923
82 / 1950
0,37 [0,25;0,56]
0
2
1.0
Relative risks
|
Endpoint |
Events (%) |
Relative Risk |
95% CI |
Endpoint definition in the trial |
Ref |
Studied treat. |
Control treat. |
cardiovascular death, MI, stroke
|
207 / 3078 (6,7%) |
252 / 3066 (8,2%) |
0,82 |
[0,69;0,98] |
CV death, MI, stroke, cardiac arrest |
|
new-onset diabetes
|
30 / 1923 (1,6%) |
82 / 1950 (4,2%) |
0,37 |
[0,25;0,56] |
|
|
cardiovascular events
|
530 / 3078 (17,2%) |
529 / 3066 (17,3%) |
1,00 |
[0,89;1,11] |
primary endpoint |
|
new-onset atrial fibrillation
|
107 / 2818 (3,8%) |
55 / 2787 (2,0%) |
1,92 |
[1,40;2,65] |
|
|
The primary endpoint (if exists) appears in blod characters
|
Reference(s) used for data extraction:
|
Endpoint |
studied treat. |
control treat. |
mean diff |
Absolute risk reduction
|
Endpoint |
Events rate |
Absolute risk reduction (ARR) |
Studied treat. |
Control treat. |
cardiovascular death, MI, stroke |
6,73% |
8,22% |
-14,9‰
|
new-onset diabetes |
1,56% |
4,21% |
-26,5‰
|
cardiovascular events |
17,22% |
17,25% |
-0,3‰
|
new-onset atrial fibrillation |
3,80% |
1,97% |
1,8%
|
Meta-analysis of all similar trials:
antioxydants in cardiovascular prevention for all type of patients
Reference(s)
-
Tardif JC, McMurray JJ, Klug E, Small R, Schumi J, Choi J, Cooper J, Scott R, Lewis EF, L'Allier PL, Pfeffer MA.
Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial..
Lancet 2008;371:1761-8
Pubmed
|
Hubmed
| Fulltext
|